Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models

Fig. 3

Combined treatment of metformin and sorafenib promoted HCC cells apoptosis and inhibited epithelial-mesenchymal transition process in hypoxia. a Cells were cocultured with metformin or sorafenib under cobalt chloride treatment for 48 h. Metformin or sorafenib impaired MHCC97H cell proliferation in a dose-dependent manner. b Cells were treated with metformin and sorafenib alone or combined at different time points in the presence of CoCl2. Combined treatment inhibited MHCC97H cell proliferation in a time-dependent manner. c About 5 × 105 MHCC97H cells were plated in 6-well plates. After treatment with metformin and sorafenib for 48 h in hypoxia, the apoptosis was detected by flow cytometry. Combined therapy significantly promoted MHCC97H cell apoptosis. d After treatment with metformin and sorafenib for 48 h in hypoxia, EMT-associated proteins were evaluated by Western blot. Sorafenib alone promoted the process of EMT, while combined treatment inhibited this effect in vitro

Back to article page